IDT, genomics solutions provider, has launched a new system to provide an end-to-end solution for characterising and quantifying the full array of on and off-target genome editing events in CRISPR research projects, and other genome editing projects.
The system uses IDT rhAmpSeq technology, which is designed to enable accurate amplicon sequencing on Illumina next generation sequencing (NGS) platforms. The rhAmpSeq CRISPR Analysis System consists of design and synthesis of a custom rhAmpSeq CRISPR Panel, an efficient library kit, and access to data analysis through a user-friendly interface. This system enables sample-to-sequencer-to-results in less than a week.
Trey Martin, IDT President, said: “As genome editing becomes more widespread, it is crucial to validate the editing and identify off-target effects. The rhAmpSeq CRISPR Analysis System addresses and uniquely enables this important researcher need.”